Agios Pharmacueticals gets $33 million

Agios Pharmacueticals, a Cambridge, Mass.-based biotech company focused on cancer metabolism, closed on $33 million in Series A funding. The round was co-led by Third Rock Ventures, Flagship Ventures and ARCH Venture Partners. Company Web site